Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EVT801 |
| Synonyms | |
| Therapy Description |
EVT801 inhibits FLT4 (VEGFR3), potentially resulting in enhanced antitumor immune response, and inhibition of tumor angiogenesis and tumor development (Cancer Res 2019;79(13 Suppl):Abstract nr 4079; Cancer Res 2017;77(13 Suppl):Abstract nr 2634). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EVT801 | EVT-801|EVT 801 | VEGFR3 Inhibitor 6 | EVT801 inhibits FLT4 (VEGFR3), potentially resulting in enhanced antitumor immune response, and inhibition of tumor angiogenesis and tumor development (Cancer Res 2019;79(13 Suppl):Abstract nr 4079; Cancer Res 2017;77(13 Suppl):Abstract nr 2634). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05114668 | Phase I | EVT801 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | Completed | FRA | 0 |